Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Iovance Biotherapeutics (IOVA) Net Income (2016 - 2025)

Iovance Biotherapeutics (IOVA) has disclosed Net Income for 13 consecutive years, with -$71.9 million as the latest value for Q4 2025.

  • On a quarterly basis, Net Income rose 8.53% to -$71.9 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$390.9 million, a 5.04% decrease, with the full-year FY2025 number at -$390.9 million, down 5.04% from a year prior.
  • Net Income was -$71.9 million for Q4 2025 at Iovance Biotherapeutics, up from -$91.3 million in the prior quarter.
  • In the past five years, Net Income ranged from a high of -$71.9 million in Q4 2025 to a low of -$116.4 million in Q4 2023.
  • A 3-year average of -$100.6 million and a median of -$106.9 million in 2023 define the central range for Net Income.
  • Peak YoY movement for Net Income: soared 32.47% in 2024, then fell 15.0% in 2025.
  • Iovance Biotherapeutics' Net Income stood at -$116.4 million in 2023, then surged by 32.47% to -$78.6 million in 2024, then grew by 8.53% to -$71.9 million in 2025.
  • Per Business Quant, the three most recent readings for IOVA's Net Income are -$71.9 million (Q4 2025), -$91.3 million (Q3 2025), and -$111.6 million (Q2 2025).